Evidence first, marketing never.
Plain-language explainers on what the research actually supports in menopause medicine. We follow The Menopause Society and ACOG, lead with body-identical estradiol and progesterone, and tell you exactly where the evidence ends.
Two datasets nobody else has
We commission and publish our own surveys, in full, with a data table under every chart. Both are free to cite with attribution.
The perimenopause productivity gap
What menopause symptoms cost women at work, and why almost nobody at work knows about them.
- 87% say symptoms disrupted their job performance in the past year
- 34.5 workdays a year lost to managing symptoms, on average
- 89% say their employer has no menopause or midlife health policy
Covered in Forbes, Fast Company.
Read the full studyMenopause in public
The daily work of staying composed: what women conceal, where, and what it costs them.
- 91% try to hide at least one symptom in public
- 57% feel pressure at work to appear unaffected
- 86% say symptoms changed how they dress
Start with the evidence
Is hormone therapy safe? What the evidence says
For most healthy women under 60 or within ten years of menopause, the benefits of hormone therapy outweigh the risks. Here is what the major trials and current guidelines say — and what they do not.
Jan 14, 2025 · 7 min readBioidentical vs compounded hormones, explained
“Bioidentical” is a marketing word, not a safety claim. Estradiol and progesterone manufactured to a tested, standardized product are body-identical and rigorously tested. Here is how to tell the categories apart — and where compounding has a legitimate, narrow role.
Feb 4, 2025 · 6 min readTreating GSM: vaginal estrogen and DHEA
Vaginal dryness, painful intimacy, and recurrent urinary symptoms rarely improve on their own — but they respond well to low-dose local therapy. Here is how vaginal estrogen and DHEA work.
Feb 25, 2025 · 6 min readTransdermal vs oral estrogen: the mechanism and the evidence
Estradiol can be delivered through the skin or swallowed as a pill — and the difference is not cosmetic. Transdermal routes bypass the liver's first pass, which appears to lower clot risk. Here is the mechanism and the evidence behind that difference.
May 6, 2026 · 7 min readEstrogen, bone loss, and fracture risk in menopause
Estrogen helps keep bone strong, and its decline drives the fastest bone loss of a woman's life in the years around menopause. Hormone therapy is an established option to prevent that loss — within an individualized, risk-aware decision.
May 13, 2026 · 7 min readEstrogen and the liver: oral vs transdermal, explained
Swallowed estrogen meets the liver before it meets the rest of you, and that single fact drives most of the route decision in hormone therapy. Here is what first-pass metabolism actually changes, and who it matters for.
Aug 22, 2026 · 7 min readFeel like yourself again.
Take the 3-minute assessment, then meet your clinician by video or phone. No obligation.
Free shipping · Cancel anytime · HSA / FSA eligible · No membership fee